Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a poly…
Sponsor: NRG Oncology
NCT ID: NCT06580314
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Alaska Breast Care and Surgery LLC — Anchorage, Alaska
+ 673 more sites in the U.S.
Phase 3 Recruiting Network
This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with alkylating agents. Alkylating agents are part of s…
Sponsor: Children's Oncology Group
NCT ID: NCT06513962
Locations: - Children's Hospital of Alabama — Birmingham, Alabama
- University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- USA Health Strada Patient Care Center — Mobile, Alabama
+ 198 more sites in the U.S.
Phase 3 Recruiting Industry
This is a clinical study that has three parts. It is testing a potential new medicine called Sofetabart Mipitecan (Sofe-M) for people with certain types of ovarian, peritoneal, and fallopian tube cancers. Part A enrolls participants with p…
Sponsor: Eli Lilly and Company
NCT ID: NCT07213804
Locations: - University of Alabama at Birmingham — Birmingham, Alabama
- HonorHealth — Phoenix, Arizona
- Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center — Burbank, California
+ 82 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.
Sponsor: Incyte Corporation
NCT ID: NCT07214779
Locations: - Alaska Womens Cancer Care Akwcc — Anchorage, Alaska
- University of Arizona Cancer Center — Tucson, Arizona
- City of Hope Medical Center — Duarte, California
+ 60 more sites in the U.S.
Phase 3 Recruiting Network
Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy given per standard institutional guidelines +/- bevacizumab on Day 1 every 21 days for 3-4 cycles. Registered patients who progress during neoadj…
Sponsor: GOG Foundation
NCT ID: NCT05659381
Locations: - City of Hope — Duarte, California
- University of California San Diego Moores Cancer Center — La Jolla, California
- Hoag Memorial Hospital Presbyterian — Newport Beach, California
+ 56 more sites in the U.S.
Phase 3 Recruiting Industry
The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer get…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06824467
Locations: - University of Alabama at Birmingham ( Site 0006) — Birmingham, Alabama
- Alaska Women's Cancer Care ( Site 0096) — Anchorage, Alaska
- City of Hope Lennar Foundation Cancer Center ( Site 0024) — Irvine, California
+ 35 more sites in the U.S.
Phase 3 Recruiting Industry
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.
Sponsor: Verastem, Inc.
NCT ID: NCT06072781
Locations: - HonorHealth — Phoenix, Arizona
- University of Arkansas — Little Rock, Arkansas
- UCLA Health — Los Angeles, California
+ 35 more sites in the U.S.
Phase 3 Recruiting Industry
This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expr…
Sponsor: Daiichi Sankyo
NCT ID: NCT06819007
Locations: - Disney Family Cancer Center — Burbank, California
- Scripps Clinic — La Jolla, California
- Palo Alto Medical Foundation — Palo Alto, California
+ 30 more sites in the U.S.
Phase 3 Recruiting Industry
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice…
Sponsor: Genelux Corporation
NCT ID: NCT05281471
Locations: - The University of South Alabama, Mitchell Cancer Institute — Mobile, Alabama
- University of Arizona Cancer Center — Tucson, Arizona
- City of Hope — Duarte, California
+ 30 more sites in the U.S.
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard ca…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07318558
Locations: - University of Alabama - Birmingham ( Site 0058) — Birmingham, Alabama
- John Muir Health Cancer Center ( Site 0069) — Walnut Creek, California
- Mount Sinai Cancer Center ( Site 0029) — Miami Beach, Florida
+ 24 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to measure the efficacy and safety of torvutatug samrotecan (torvu-sam) with or without bevacizumab compared to standard of care (SoC) as maintenance treatment in participants with platinum-sensitive relapsed o…
Sponsor: AstraZeneca
NCT ID: NCT07816666
Locations: - Research Site — Anchorage, Alaska
- Research Site — Miami, Florida
- Research Site — Indianapolis, Indiana
+ 23 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy before and after surgery (neoadjuvant…
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT04575935
Locations: - University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
- Cleveland Clinic Foundation - Florida — Weston, Florida
- Massachusetts General Hospital — Boston, Massachusetts
+ 10 more sites in the U.S.